Restenosis Intra-Stent of Drug-Eluting Stents: Drug-Eluting Balloon vs Everolimus-Eluting Stent | Clinical Trial - RIBS IV


The optimal treatment of drug-eluting stent (DES)–in-stent restenosis (ISR) remains challenging. The current trial sought to investigate outcomes after drug-eluting balloon (DEB) versus DES implantation for patients with DES-ISR.

Contribution to the Literature: The RIBS IV trial showed that everolimus-eluting stents are superior to drug-coated balloon for the treatment of DES-ISR.